Paz-Arez L, Villegas A, Daniel D, et al. LBA1_PR - PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC. ESMO 2017 Congress; LBA1_PR.
Toegang tot zorg bij vroegstadium longkanker in Europa moet beter
mrt 2024 | Immuuntherapie, Longoncologie